MedTrace Logo

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

NCT06745531 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2025-11-17

No results posted yet for this study

Summary

A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia

Conditions

  • Hyperphosphatemia Patients on Hemodialysis

Interventions

DRUG

TS-172 20~60 mg/day

oral administration of TS-172 20\~60 mg/day

DRUG

Placebo

oral administration of placebo

Sponsors & Collaborators

  • Taisho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taisho Director · Taisho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-06
Primary Completion
2025-10-13
Completion
2025-10-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06745531 on ClinicalTrials.gov